OBJECTIVES: To compile the body of evidence and produce a HTA on IGB in morbidly obese (MOP) and super obese (BMI ≥ 50) patients. To evaluate the impact on IGB on weight loss, co-morbidities (CM), reduction of post-operatory complications on bariatric surgery. METHODS: We performed a SR on Medline and Cochrane Library among other databases, including articles published until January 2010. We searched “Gastric Balloon[Mesh]”, “intragastric balloon”, “Comparative Study [Publication Type]”, “Randomized Controlled Trial [Publication Type]”, “random*” e “systematic[sb]”. RESULTS: We found two SR without meta-analysis (MA), two SR with MA and two randomized controlled clinical trials (RCCT). In MOP the use of IGB does not improve the weight loss compared to diet (Level of Evidence 1b). There are no long term efficacy data available and there might be a weight gain after the IGB is withdrawn. The risk of minor complications (gastric ulcer and abdominal pain) but not of major complications (intestinal obstruction and esophageal laceration) is greater in patients using IGB (LE 1b). For SOP there is insufficient evidence to support that the use of IGB before bariatric surgery reduces the conversion rate from laparoscopic to open surgery or the intra-operatory complication risks (LE 4). There is a lack of evidence on the impact of IGB use on CM such as diabetes, hypertension or sleep apnea for both MOP and SOP. CONCLUSIONS:  For MOP there is evidence that the use of IGB does not lead to greater weight loss compared to diet and it increases the risk of minor complications (LE 1b). For SOP there is insufficient evidence of effectiveness and safety to support the use of IB as a previous step before gastric bypass surgery. For both, there is a lack of evidence on the impact of IGB on CM.